Over the past two decades, the arsenal of disease-modifying therapies for multiple sclerosis (MS) has expanded considerably. This applies in particular to the relapsing-remitting form (RRMS), but the treatment options for the other subtypes have also improved. The evidence base for what is currently the only immunomodulatory therapy for primary chronic progressive MS (PPMS) has recently been expanded by several new studies.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Prostate cancer
High-resolution ultrasound could diagnose prostate cancer faster
- Chronic lung diseases
Sarcopenia and malnutrition in the context of pneumological rehabilitation
- Blastic plasmacytoid dendritic cell neoplasia
Rare malignancy from a dermatological perspective
- Psychooncology
Communication as the key to therapy adherence
- From symptom to diagnosis
Lung carcinoma – Pancoast tumor
- Deep vein thrombosis
Outpatient or inpatient treatment?
- From symptom to diagnosis
Abdominal pain – Intraductal papillary mucinous neoplasia
- IBDmatters - Advanced Therapeutic Treatments